🔎 Trials Near Me

Beranda › Limfoma Zona Marginal › Ohio

Uji klinis Limfoma Zona Marginal di Ohio

13 studi untuk Limfoma Zona Marginal mencari peserta di lokasi di Ohio.

Kota di Ohio

Teks studi resmi (Bahasa Inggris)

Epco, Zanu, Ritux for R/R FL or MZL

  • The Ohio State University Wexner Medical Center, Columbus
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06563596

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

  • Licking Memorial Hospital, Newark
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT04840602

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • Cleveland Clinic, Cleveland
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07101328

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

  • Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07225439

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • The Ohio State University Wexner Medical Center, Columbus
Menerima pesertaFase 1/2
Usia 13 hingga 90 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06533579

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

  • University of Cincinnati, Cincinnati
  • The Ohio State University, Columbus
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT06708897

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • University of Cincinnati Medical Center, Cincinnati
  • Cleveland Clinic, Cleveland
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT05131022

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

  • Ohio Health Riverside Methodist Hospital, Columbus
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jun 2026 · NCT05700149

Study of SGR-1505 in Mature B-Cell Neoplasms

  • Gabrail Cancer & Research Center, Canton
  • The Ohio State University - The James Cancer Hospital, Columbus
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Feb 2026 · NCT05544019

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

  • University of Cincinnati, Cincinnati
  • Ohio State University, Columbus
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Feb 2026 · NCT04775745

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

  • Taylor Cancer Research Center, Maumee
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Des 2025 · NCT05602363

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Cincinnati
  • Massive Bio SYNERGY-AI site, Columbus
  • Massive Bio SYNERGY-AI site, Mayfield Heights
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

  • University Hospitals Cleveland Medical Center, Cleveland
  • The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2025 · NCT05780034

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.